Abstract
Biogenetically produced authentic GH (r-HGH) of mammalian cell origin was used in a multicenter treatment trial involving GH deficient children from Austria, FRG, GDR and Switzerland after approval by ethical committees. GH was applied s.c. daily in a dose of 12 U/m2/week. Previously with GH treated (group T) and untreated (group U) patients were included. 65 patients met the selection criteria. Group U consisted of 20 males and 9 females, mean age 7.59±4.1 (SD) y, mean bone age (BA) 5.12 ± 3.43 y. Group T enclosed 28 males, 8 females, mean age 9.66 ± 3.48 y, mean BA 6.57 ± 3.01 y, pituitary GH was stopped for a period of time before r-HGH started. Results: After 6 months of treatment: Group U: Mean growth velocity increased from 3.06 ± 0.81 to 10.26 ± 2.5 cm/y, mean height standard deviation score (SDS) for age was reduced from -3.45 ± 1.27 to -2.97 ± 1.1 and height age (HA): BA ratio increased from 1.02 ± 0.24 to 1.12 ± 0.33. Group T: Growth velocity increased from 3.16 ± 1.98 to 8.8 ± 2.35 cm/y, mean height SDS was reduced from -2.73±1.91 to -2.42 ± 1 .76. HA: BA ratio improved from 0.97 ± 0.27 to 1.08 ± 0.26. In both groups Somatomedin C levels rose. One of 65 children developed GH antibodies, no antibodies to non r-HGH-protein could be detected. No clinically visible side effects were observed. Conclusion: This new type of r-HGH is effective and an alternative to r-HGH produced in E. coli bacteria.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stybbe, P., Stahnke, N. R-HGH OF MAMMALIAN CELL ORIGIN FOR THE TREATMENT OF GROWTH HORMONE (GH) DEFICIENCY IN CHILDREN. Pediatr Res 23, 116 (1988). https://doi.org/10.1203/00006450-198801000-00091
Issue date:
DOI: https://doi.org/10.1203/00006450-198801000-00091
